News
J&J's Balversa is first pan-FGFR bladder cancer drug in EU
Johnson & Johnson's Balversa has become the first drug approved in the EU to treat adults with advanced urothelial carcinoma (mUC) with FGFR3 genetic alterations after one line of prior
